About Zinc finger protein 239
Zinc finger protein 239 (ZNF239) is a protein
from Homo sapiens identified by UniProt accession
Q16600, 458 residues long.
MolForge cross-references it against 0 known binders and
25 disease associations.
Target properties
| Protein name | Zinc finger protein 239 |
| UniProt accession | Q16600 |
| Gene | ZNF239 |
| Organism | Homo sapiens |
| Length | 458 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (25)
Diseases linked to this target (Open Targets).
- type 2 diabetes mellitus · score 0.27
- coronary artery disease · score 0.12
- myocardial infarction · score 0.12
- cortical surface area measurement · score 0.10
- brain measurement · score 0.10
- angina pectoris · score 0.10
- heel bone mineral density · score 0.09
- coronary artery bypass · score 0.08
- vertebral disorder · score 0.07
- cystatin C measurement · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q16600-F1 | alphafold | PREDICTED | 62.58 | — |
Amino-acid sequence (458 residues)
MASTITGSQD CIVNHRGEVD GEPELDISPC QQWGEASSPI SRNRDSVMTL QSGCFENIES ETYLPLKVSS QIDTQDSSVK FCKNEPQDHQ ESRRLFVMEE STERKVIKGE SCSENLQVKL VSDGQELASP LLNGEATCQN GQLKESLDPI DCNCKDIHGW KSQVVSCSQQ RAHTEEKPCD HNNCGKILNT SPDGHPYEKI HTAEKQYECS QCGKNFSQSS ELLLHQRDHT EEKPYKCEQC GKGFTRSSSL LIHQAVHTDE KPYKCDKCGK GFTRSSSLLI HHAVHTGEKP YKCDKCGKGF SQSSKLHIHQ RVHTGEKPYE CEECGMSFSQ RSNLHIHQRV HTGERPYKCG ECGKGFSQSS NLHIHRCIHT GEKPYQCYEC GKGFSQSSDL RIHLRVHTGE KPYHCGKCGK GFSQSSKLLI HQRVHTGEKP YECSKCGKGF SQSSNLHIHQ RVHKKDPR
Explore Zinc finger protein 239 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets